Relmada Therapeutics, Inc. (RLMD)

7.32 -0.54 (-6.87%) USD  |  NASDAQ  |  May 07, 13:29
More

Relmada Therapeutics SG&A Expense (TTM) : 32.22M for Dec. 31, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for RLMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Catalyst Pharmaceuticals, Inc. 171.18M
Theravance Biopharma, Inc. 78.40M
Avalo Therapeutics, Inc. 22.90M
AN2 Therapeutics, Inc. 13.34M
ACADIA Pharmaceuticals, Inc. 548.89M